The characterisation of molecular abnormalities in patients with lung cancers has led to the development of a number of targeted therapies, mainly based on mutations in the EGFR, ALK or KRAS genes

Authors
Marie Wislez, Hôpital Cochin AP-HP, Paris Descartes, Paris, France
Authors
Marie Wislez, Hôpital Cochin AP-HP, Paris Descartes, Paris, France
Category
Oncology
Publication type
Proceedings
Year
2019
Download the publication